Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

78.90USD
23 Feb 2018
Change (% chg)

$0.96 (+1.23%)
Prev Close
$77.94
Open
$78.34
Day's High
$79.62
Day's Low
$77.14
Volume
100,169
Avg. Vol
210,924
52-wk High
$82.06
52-wk Low
$20.39

Latest Key Developments (Source: Significant Developments)

Esperion Reports Qtrly Loss Per Share $1.44
Tuesday, 20 Feb 2018 07:30am EST 

Feb 20 (Reuters) - Esperion Therapeutics Inc ::ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION.ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE ABOUT $130 TO $140 MILLION AT DEC 31, 2018.ESPERION THERAPEUTICS INC - QTRLY LOSS PER SHARE $1.44.  Full Article

Esperion Therapeutics Q3 loss per share $1.86‍​
Tuesday, 7 Nov 2017 08:00am EST 

Nov 7 (Reuters) - Esperion Therapeutics Inc :Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results.Expects full-year 2017 net cash used in operating activities to be approximately $135 million​.Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31.Estimates cash resources are sufficient to fund operations through Q1 2020​.Qtrly loss per share $1.86‍​.Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S.  Full Article

Esperion announces initiation of pivotal late stage study for bempedoic acid
Monday, 6 Nov 2017 04:30pm EST 

Nov 6 (Reuters) - Esperion Therapeutics Inc :Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill.Esperion Therapeutics - ‍NDA submission for LDL-C lowering indication for bempedoic acid / ezetimibe combination pill expected by Q1 2019​.Esperion Therapeutics Inc - ‍top-line results expected by q4 of 2018 for bempedoic acid / ezetimibe combination pill​.  Full Article

Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018
Monday, 2 Oct 2017 04:30pm EDT 

Oct 2 (Reuters) - Esperion Therapeutics Inc :Esperion Therapeutics- bempedoic acid top-line results from studies 1, 3 and 4 are expected in Q2 2018, results from study 2 expected in Q3 2018.Esperion Therapeutics Inc - NDA submission for LDL-C lowering indication for bempedoic acid planned by Q1 2019.Esperion - pivotal Phase 3 program for bempedoic acid/ezetimibe combination pill on track to initiate this quarter, top-line results expected by Q4 2018.  Full Article

Esperion prices public offering of common stock at $49 per share
Wednesday, 9 Aug 2017 09:20pm EDT 

Aug 9 (Reuters) - Esperion Therapeutics Inc :Esperion prices public offering of common stock.Announces public offering of 3.1 million shares of its common stock, offered at a price to public of $49.00 per share.  Full Article

Esperion announces proposed public offering of common stock
Tuesday, 8 Aug 2017 04:31pm EDT 

Aug 8 (Reuters) - Esperion Therapeutics Inc ::Esperion announces proposed public offering of common stock.Says ‍intends to offer and sell $150 million of its common stock in an underwritten public offering​.Esperion Therapeutics - to use net proceeds from offering, other existing capital resources, to fund clear outcomes cardiovascular outcomes trial​.  Full Article

Co announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Esperion Therapeutics Inc :Says Esperion announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​.Says ‍1002-038 study meets primary endpoint with a robust 64% LDL-C lowering efficacy​.Says ‍combination therapy was observed to be safe and well-tolerated​.Says ‍there were no reported serious adverse events (SAES), no difference in muscle-related adverse events​.  Full Article

Esperion reports initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor
Wednesday, 26 Jul 2017 04:30pm EDT 

July 26 (Reuters) - Esperion Therapeutics Inc ::Esperion announces initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor.Esperion therapeutics inc- ‍top-line results are expected by q1 of 2018 from study​.Esperion therapeutics inc- ‍we don't intend to explore bempedoic acid added-on to a pcsk9i in further studies due to their limited use to date​.Esperion therapeutics- ‍in phase 2 study, anticipate will see favorable safety, tolerability and incremental ldl-c lowering efficacy from bempedoic acid​.  Full Article

Esperion says FDA confirms regulatory pathway to approval its combination cholestrol treatment
Monday, 26 Jun 2017 04:05pm EDT 

June 26 (Reuters) - Esperion Therapeutics Inc -:Esperion announces FDA confirmation of regulatory pathway to approval for the combination of bempedoic acid and ezetimibe.Says phase 3 bempedoic acid / ezetimibe combination bridging study to initiate by Q4 of 2017.Esperion Therapeutics - on track to submit both bempedoic acid / ezetimibe combination and bempedoic acid global regulatory filings for an ldl-c lowering indication by h1 2019.Esperion Therapeutics says top-line results for for the bempedoic acid / ezetimibe combination pill trial expected by end of 2018.  Full Article

Esperion reports Q1 net loss per common share $1.80
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Esperion Therapeutics Inc :Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results.Esperion Therapeutics Inc - esperion expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million.Qtrly net loss per common share $1.80.  Full Article

BRIEF-Esperion Reports Qtrly Loss Per Share $1.44

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS